Our healthcare and business law firm advises many physicians and medical practices on compliantly using telemedicine to provide medical care to patients. Typically, the Federal Ryan Haight Act requires at minimum an in-person evaluation before prescribing controlled substances. Since the COVID-19 Pandemic, however, the Federal Drug Enforcement Administration (“DEA”) and the Health and Human Services Department (“HHS”) have permitted flexibility to that rule by allowing all DEA-registered practitioners to prescribe schedule II-V controlled substances via telemedicine. The COVID-era flexibilities have been scheduled to end many times now, but the DEA and HHS continue to extend the flexibilities. Most recently, the DEA and HHS issued the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, extending the flexibilities until December 31, 2026. For each extension thus far, the Georgia Medical Board has also permitted parallel flexibilities in Georgia. This post discusses the Georgia Medical Board’s current stance on telemedicine flexibilities for prescribing controlled substances. If you would like to discuss using telemedicine in a medical practice or this blog post, you may contact our healthcare and business law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.
Georgia’s General Tele-Prescribing Rule
Georgia Rule 360-3-.02 defines Unprofessional Conduct to include: “Prescribing controlled substances . . . and/or dangerous drugs . . . for a patient based solely on Continue reading ›
























